NEW YORK (GenomeWeb) – Trovagene said today that it has entered into an agreement with Chinese genomics service provider Novogene under which Novogene will validate Trovagene's proprietary urine collection and nucleic acid preservation device, NextCollect, and develop tests for the Chinese market.

Trovagene is selling Novogene the NextCollect device along with reagents and methods to extract cell-free DNA (cfDNA) from urine. Novogene will then validate the platform at its own facilities, which include a CAP-accredited lab in Tianjin, China.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.